Findings

What do systematic reviews say?

9 questions · 9 findings · 5 reviews

No studies found 8 · 88.9%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 11.1%Moderate 0 · 0%High 0 · 0%

Quality of life · people with non‐transfusion‐dependent β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quality of life · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quality of life ‐ not reported · prevention of SCI in people with SCD who have not had a stroke (primary prevention)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quality of life ‐ not reported · prevention of SCI in people with SCD who had a stroke (secondary prevention)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quality of life · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Change in quality of life · children and adults with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quality of life · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quality of life · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Health status and quality of life · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 277 participants
Low